Forte Biosciences Inc (FBRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Forte Biosciences Inc (FBRX) has a cash flow conversion efficiency ratio of -0.166x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.00 Million) by net assets ($84.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see FBRX market cap for the company's overall valuation and market capitalisation.
Forte Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Forte Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Forte Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Forte Biosciences Inc ranked by their cash flow conversion efficiency. See FBRX operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vina San Pedro
SN:VSPT
|
0.001x |
|
Wismilak Inti Makmur Tbk
JK:WIIM
|
0.040x |
|
Cartesian Therapeutics Inc.
NASDAQ:RNAC
|
0.149x |
|
New World Resources Ltd
AU:NWC
|
-0.015x |
|
IKIO Lighting Limited
NSE:IKIO
|
0.008x |
|
Syscom Computer Engineering Co
TW:2453
|
0.039x |
|
VIB Vermögen AG
XETRA:VIH1
|
0.018x |
|
CVW Sustainable Royalties Inc.
V:CVW
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Forte Biosciences Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Forte Biosciences Inc from 2015 to 2024. View Forte Biosciences Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-30.75 Million | -0.586x | +27.93% |
| 2023-12-31 | $35.31 Million | $-28.71 Million | -0.813x | -285.51% |
| 2022-12-31 | $38.82 Million | $-8.19 Million | -0.211x | +47.47% |
| 2021-12-31 | $41.55 Million | $-16.68 Million | -0.401x | -28.50% |
| 2020-12-31 | $58.98 Million | $-18.42 Million | -0.312x | +35.23% |
| 2019-12-31 | $5.75 Million | $-2.77 Million | -0.482x | +18.65% |
| 2018-12-31 | $58.15 Million | $-34.47 Million | -0.593x | -35.35% |
| 2017-12-31 | $71.08 Million | $-31.13 Million | -0.438x | +89.63% |
| 2016-12-31 | $7.00 Million | $-29.54 Million | -4.222x | -684.24% |
| 2015-12-31 | $39.08 Million | $-21.04 Million | -0.538x | -- |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more